Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07665437 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07665437 · ClinicalTrials.gov record · last posted 2026-08-18

An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

Name: An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS — clinical trial record (NCT07665437)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorNovartis Pharmaceuticals

Started2026-07-10

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of remibrutinib (LOU064) in adult participants with moderate to severe hidradenitis suppurativa (HS) who have completed either of the preceding Phase 3 studies, CLOU064J12301 or CLOU064J12302.

Protocol amendment history 3 changes detected by DataLookout

2026-08-19

Trial sites expanded: 4 → 11 locations

2026-07-16

Recruitment opened

2026-07-16

Trial sites expanded: 0 → 4 locations

Trial Details

NCT Number	NCT07665437
Lead Sponsor	Novartis Pharmaceuticals
Conditions	Hidradenitis Suppurativa
Enrollment	710 participants
Start Date	2026-07-10
Primary Completion	2031-10-27 (estimated)
Study Completion	2031-10-27 (estimated)
Updated on ClinicalTrials.gov	2026-08-18